Skip to main content

Conference Program

Subpage Hero

Loading

Platform Presentations - Cancer Genetics and Therapeutics / Research Methods & Resources

14 Mar 2024
Venue: MTCC
Meeting Room: 714/16
Research Methods , Cancer Genetics and Therapeutics
  • Accredited:
    • Accredited
Platform presentations are abstract submissions chosen by the abstract review committee to orally present their research. It is a 13-minute presentation followed by a 2-minute Q&A.

O40 - UNC EDGE: An Undergraduate Genomics Experience to Foster Diversity in Genomics
O12 - Clonal hematopoiesis-related variants confounding hereditary cancer testing: Results from matched tumor-normal sequencing of 26,329 cancer patients
O04 - Evaluation of the performance of the Bayesian point system on the variant classification of hereditary cancer predisposition genes
O41-  A Canadian Lab's Clinical Validation Experience With Optical Genome Mapping As a Front-Line Diagnostic Test for Hematological Neoplasms
O29 - Low Rate of Hereditary Ovarian Cancer Screening in Individuals Meeting National Comprehensive Cancer Network Guidelines
O06 - Penetrance and Prevalence of CDKN2A Pathogenic Variants in a Large Institutional Cohort: Scrutinizing the Common p.Ile49Thr Variant 
 

Agenda

  • Marc Tischkowitz, MD, PhD
  • Sabrina N. Powell, PhD
    UNC EDGE: An Undergraduate Genomics Experience to Foster Diversity in Genomics
    4:15 PM – 4:30 PM
  • Ozge Birsoy, PhD
    Clonal hematopoiesis-related variants confounding hereditary cancer testing: Results from matched tumor-normal sequencing of 26,329 cancer patients 

     
    4:30 PM – 4:45 PM
  • Mohammad K. Eldomery, MD
    Evaluation of the performance of the Bayesian point system on the variant classification of hereditary cancer predisposition genes
    4:45 PM – 5:00 PM
  • Zeid ZH. Hamadeh, Zeid Hamadeh
    A Canadian Lab's Clinical Validation Experience With Optical Genome Mapping As a Front-Line Diagnostic Test for Hematological Neoplasms
    5:00 PM – 5:15 PM
  • Jacklyn Omorodion, MD
    Low Rate of Hereditary Ovarian Cancer Screening in Individuals Meeting National Comprehensive Cancer Network Guidelines
    5:15 PM – 5:30 PM
  • Michael L. Restrepo, MS, CGC
    Penetrance and Prevalence of CDKN2A Pathogenic Variants in a Large Institutional Cohort: Scrutinizing the Common p.Ile49Thr Variant 
    5:30 PM – 5:45 PM

Sponsors